Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer

Hiroshi Okamoto, Yusuke Taniyama, Tadashi Sakurai, Takahiro Heishi, Jin Teshima, Chiaki Sato, Shota Maruyama, Ken Ito, Yu Onodera, Takuro Konno-Kumagai, Hirotaka Ishida, Takashi Kamei

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Background: Recently, definitive chemoradiotherapy (dCRT) has become one of the essential treatment strategies for esophageal squamous cell carcinoma (ESCC) and has been especially gaining prevalence for cervical ESCC to preserve the larynx. Our department recently introduced dCRT concomitant with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for treating advanced cervical ESCC. This study aims to assess the safety and outcomes of DCF-R in patients with advanced cervical ESCC. Methods: We retrospectively assessed 11 patients with advanced cervical ESCC (clinical stage: II–IV, including T4b and/or M1 lymph node) who received DCF-R as the first-line treatment between December 2010 and February 2015. Results: Our patient cohort comprised 8 males and 3 females (median age 68 years; range 54–76 years). The pretreatment clinical stage included stage II (1), stage III (7), and stage IV (3) cases [including 3 patients with T4b (2 trachea and 1 thyroid) and 3 patients with M1 lymph node]. We attained complete response (CR) in 10 patients and stable disease in 1 patient. Of 10 patients with CR, 5 experienced recurrence and 5 continued exhibiting CR. Furthermore, grade 3 or more adverse events included leucopenia (91%), neutropenia (91%), febrile neutropenia (45%), and pharyngeal pain (55%). While the 2-year overall survival rate was 72%, the 2-year recurrent-free survival rate was 64%, respectively. Conclusions: DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation.

Original languageEnglish
Pages (from-to)281-285
Number of pages5
JournalEsophagus
Volume15
Issue number4
DOIs
Publication statusPublished - 2018 Oct 1

Keywords

  • 5-Fluorouracil
  • Chemoradiotherapy
  • Cisplatin
  • Docetaxel
  • Esophageal squamous cell carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer'. Together they form a unique fingerprint.

Cite this